Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

Cannula for Ocular Micro-Injection

Country of Origin: Germany
Reference Number: TODE20171103001
Publication Date: 3 November 2017

Summary

A German company, which is active in commercializing innovations from 33 research institutes in Bavaria, offers intellectual property rights (IPR) for a medical technology: 
A cannula for ocular micro-injection, which can be addressed for targeted intra- and sub-retinal injections  to cure age-related macular degeneration (AMD).They are looking for interested parties to enter into a licensing agreement.

Description

The primary, but not the only, application of this cannula is intra- and sub-retinal targeted administration of drugs and stem-cells to cure age-related macular degeneration (AMD). The other pathologies such as retinal vein occlusion and retinal diseases are alternative applications of this technology. A catheter principle is addressing a serious clinical challenge in ocular micro-injection which is the lack of ergonomic positioning for inserting a bent-tip needle with appropriate position and orientation.To facilitate efficient treatment of both forms of AMD, ophthalmologists suggested targeted delivery of sub-retinal substances. The technology helps to facilitate efficient treatment of AMD by a targeted delivery of intra- and sub-retinal substances. AMD patients, the first and direct target group with 8.7 % prevalence among people older than 45 can benefit from this newly invented system. AMD is the leading cause of blindness in developed countries and this disease is expanding from 178 million cases in 2014 to 196 million cases in 2020. 
The current utilities were up to now not appropriate for such an injection.
This cannula system is the only one which comprises intuitive and ergonomic intra- and sub-retinal injection/suction with only one degree of freedom (DOF) for catheter advancement. Therefore the system enables a very high precision. The technology has already been prototyped with larger diameter and it has been tested by eye surgeons on pig eyes under OCT integrated ophthalmic microscope. They are now looking for industry partners in the field of ophthalmological surgery instruments to licence this new technology.
Image

Advantages and Innovations

-	New cannula system is designed to address targeted intra- and sub-retinal injection
- Only cannula comprising intuitive and ergonomic intra- and sub-retinal injection with only one degree of freedom (DOF) for catheter advancement
- Two-channel system provides very high precision

Stage Of Development

Prototype available for demonstration

Stage Of Development Comment

The technology has already been prototyped with a larger diameter (20G) and tested on pig eyes under OCT integrated ophthalmic microscope.

Requested partner

The agency looks for industry partners in the field of ophthalmological surgery instruments to licence this new technology.

Cooperation offer ist closed for requests